ABOUT EFFLUX PUMP INHIBITION


TAXIS has identified numerous efflux pump inhibitor (EPI) candidate compounds that are synergistic with a wide range of currently marketed antibiotic agents, and thereby resurrect activity of these drugs,  providing low-cost access to life-saving medications.

ABOUT FtsZ MODULATION

The bacterial protein FtsZ plays an essential role in bacterial cell division and survival. TXA709, TAXIS’s most advanced drug candidate, modulates FtsZ by blocking post-mitotic septum formation within the bacterial cell.

ABOUT MREB MODULATION


MreB is a bacterial protein involved in maintaining the shape of rod-shaped bacteria such as Escherichia coli. Inhibition of MreB undermines bacterial cell shape integrity, polar protein localization and/or chromosome segregation.

Tackling the Antimicrobial Resistance Crisis


Overuse and misuse of antibiotic agents have contributed to the spread of resistant bacteria, posing a serious health risk that the World Health Organization (WHO) describes as a global health emergency. TAXIS is focused on developing new classes of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections.

Mission Statement


Our mission is to discover and develop unique therapeutic agents to address the global health crisis of antimicrobial resistance.